Very nice RT @TumorBoardTuesday: 4/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc
⌚️Understanding timing of onset helps us better understand, differentiate, & manage TKI & ICI-related AEs 👇
Next #TumorBoardTuesday 🧵 you may have missed
⏪ Rewind ⏪ to our fabulous fireside chat featuring a brief discussion on safety & management of #EndometrialCancer with @DrMMurphy @drteplinsky
Sit back & listen while grabbing a bite to eat.
#gyncsm
---
RT @TumorBoardTues
💥#EndometrialCancer TKI/IO safety data & AE mgmt webinar 💥┈┈┈ w @DrMMurphy & @drteplinsky ┈┈┈🔹#CME info 👉 http://bit.ly/3Vqtabi 👈 @BonumCe ┈┈┈🔸Supported by edu gra…
https://twitter.com/TumorBoardTues/status/1616239139082625024
In partnership with Tumor Board Tuesday, this CME-certified, Twitter-based video Fireside Chat will assess safety of anti-angiogenic therapy and immune checkpoint inhibitor treatments, particularly when used in combinations in Endometrial Carcinoma (EC). Strategies to prevent, evaluate and manage co
8/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc #EndometrialCancer
🔴#PostTest Q4️⃣
During treatment w pembro + lenva, pt develops grade 3 HTN
🔴What is the most effective mgmt strategy for this patient? (CS = corticosteroid)
6/#TumorBoardTuesday #BonumCE #GynCSM #EndometrialCancer
#CME 🔗http://bit.ly/3hYxu3R
🔴#PostTest Q 2️⃣
📊During tx w pembro + lenva, pt develops grd 3 diarrhea
🛑Lenva held
💊Loperamide Rx
Grade3️⃣diarrhea persists
🔴Which is the appropriate next step for this pt?
5/ Thanks #TumorBoardTuesday & #gyncsm!
🏆Claim #CME http://bit.ly/3hYxu3R
⬇️Answer #PostTest👇
🔴#PostTest Q1️⃣
📊Diarrhea, nausea, & vomiting are common GI tox associated w pembro + lenvatinib combo tx
🔴Which other tox may occur if these GI tox r not effectively managed?
Very nice RT @TumorBoardTuesday: 4/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc
⌚️Understanding timing of onset helps us better understand, differentiate, & manage TKI & ICI-related AEs 👇
4/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc
⌚️Understanding timing of onset helps us better understand, differentiate, & manage TKI & ICI-related AEs 👇
3/#TumorBoardTuesday #gyncsm #OncTwitter
🤔Missed the #EndometrialCancer #MedTweetorial earlier this wk?
🤯Feeling left behind?
Don't fret, it's here📍
---
RT @BonumCe
1/ #OncTwitter #TumorBoardTuesday
✅#EndometrialCancer #MedTweetorial🧵
w @DrMMurphy @MeganLeigh127 @TumorBoardTues
🧬Tx response
🧪Trial results
🔬Tox for TKI-ICI
🆓#CME 🔗 http://bit.ly/3VBGJEJ
Supported by educational grants from Eisai & @Merck
https://twitter.com/BonumCe/status/1615519240542646275
In partnership with Tumor Board Tuesday, this CME-certified, Tweetorial reviews the latest data related to anti-angiogenic therapies and immune checkpoint inhibitors in Endometrial Carcinoma (EC). An assessment of associated toxicities of these agents will lead learners to evaluate how these toxicit
3/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc #EndometrialCancer
🟠Earn 🆓 #CME 🏆
🟠#CME ℹ️🔗http://bit.ly/3YRDkog
📸 Faculty disclosures & important CME info 👇
In partnership with Tumor Board Tuesday, this CME-certified, Twitter-based video Fireside Chat will assess safety of anti-angiogenic therapy and immune checkpoint inhibitor treatments, particularly when used in combinations in Endometrial Carcinoma (EC). Strategies to prevent, evaluate and manage co